Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
arcabio.com

See what CB Insights has to offer

Founded Year

2005

Stage

PIPE - II | IPO

Market Cap

0.03B

Stock Price

2.25

Revenue

$0000 

About ARCA Biopharma

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA began operations in 2005 and is headquartered in Denver, Colorado.

ARCA Biopharma Headquarter Location

8001 Arista Place Suite 200

Broomfield, Colorado, 80021,

United States

720-940-2200

Latest ARCA Biopharma News

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

Dec 2, 2021

Topline readout of clinical trial results anticipated in first quarter of 2022 WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in ASPEN - COVID - 19 , the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19. 160 patients were enrolled at clinical investigative sites in the United States, Argentina and Brazil. The Company anticipates reporting topline data from the clinical trial in the first quarter of 2022. ASPEN-COVID-19 is a Phase 2b randomized, multi-center, international clinical trial evaluating two dose regimens of rNAPc2 versus heparin in hospitalized SARS-CoV-2 positive patients that also have an elevated D-dimer level. The primary endpoint of the trial is the change in D-dimer level from baseline to Day 8 relative to standard of care heparin. D-dimer is a biomarker commonly used for assessing coagulation activation, which is elevated in approximately 40% to 75% of hospitalized COVID-19 patients and is associated with adverse clinical outcomes. Heparin is an anticoagulant commonly given to any patient hospitalized in the United States for COVID-19. Other objectives of Phase 2b are to assess safety, determine the optimal dose regimen of rNAPc2 for a potential Phase 3 clinical trial and evaluate multiple additional clinical endpoints. Detailed information about the ASPEN-COVID-19 clinical trial is available at its listing on clinicaltrials.gov . Dr. Michael Bristow , ARCA’s President and Chief Executive Officer, commented, “Completing enrollment in ASPEN-COVID-19 is a significant milestone for the development of rNAPc2 as a potential treatment option for patients hospitalized with COVID-19 who have biomarker evidence of coagulopathy. We are grateful to the patients, their families, investigators and clinical research sites that are participating in the trial. We look forward to sharing the top-line trial results in the first quarter of next year and reviewing the findings with the FDA.” The U.S. Food and Drug Administration (FDA) has designated the investigation of rNAPc2 as a potential treatment for COVID-19 as a Fast Track development program. ARCA believes that rNAPc2 is the only anticoagulant class new chemical entity in development for COVID-19. About rNAPc2 (AB201) rNAPc2 is a small recombinant protein being developed as a potential treatment for COVID-19 and potentially other viral diseases. rNAPc2 is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral infections and in the process of viral dissemination. Its unique mechanism of action gives rNAPc2 a combination of anti-coagulant, anti-inflammatory and potential anti-viral properties, and therefore may be effective in addressing the impact of viral infections from multiple pathways. rNAPc2 has previously undergone Phase 1 and Phase 2 testing in more than 700 patients, including in clinical studies for prevention of venous and arterial thrombosis, where it showed efficacy in inhibiting the TF pathway and was well tolerated at therapeutic doses. Recent research suggests that the disease syndrome caused by coronavirus may have much in common with other severe infections in which the infection process causes inappropriate activation of the coagulation system and other aspects of the immune response, resulting in serious complications. Recent mechanistic discoveries, as well as prior data from studies in non-human primates (NHPs) given lethal doses of Ebola or Marburg filoviruses demonstrating morbidity and mortality reductions, decreases in inflammatory biomarkers and reduction in viral load, indicate that rNAPc2 may have important antiviral and anti-inflammatory activity in addition to its anticoagulant effects. The Company believes that collectively these observations provide a strong rationale for investigating rNAPc2 as a treatment for COVID-19 and other virus associated diseases. About ARCA biopharma ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. The U.S. FDA has granted Fast Track designation to the rNAPc2 development program, currently in Phase 2 clinical testing. ARCA is also developing GencaroTM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement. For more information, please visit www.arcabio.com or follow the Company on LinkedIn . Safe Harbor Statement This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding potential future development plans for rNAPc2, the expected features and characteristics of rNAPc2, the anticipated development timeline for rNAPc2, rNAPc2’s potential to treat COVID-19, or any other RNA virus associated disease, whether rNAPc2 is the only anticoagulant class new chemical entity in development for COVID-19 and the potential future treatment options and needs for patients with COVID-19. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA’s financial resources and whether they will be sufficient to meet its business objectives and operational requirements; ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of rNAPc2 or to otherwise continue operations in the future; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the Securities and Exchange Commission, including without limitation ARCA’s annual report on Form 10-K for the year ended December 31, 2020, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements. Investor & Media Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ARCA Biopharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ARCA Biopharma is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

ARCA Biopharma Patents

ARCA Biopharma has filed 17 patents.

The 3 most popular patent topics include:

  • Beta blockers
  • Alpha blockers
  • Amines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/5/2020

2/23/2021

Cardiac arrhythmia, Beta blockers, Antiarrhythmic agents, Heart diseases, Amines

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/5/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/23/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Cardiac arrhythmia, Beta blockers, Antiarrhythmic agents, Heart diseases, Amines

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

ARCA Biopharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ARCA Biopharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.